Siemens' Big Plans for AI and Life Sciences

Roland Busch, CEO of Siemens AG, is setting his sights on significant advancements in artificial intelligence, life sciences, and operations software.

Data is King

Busch envisions a future where data reigns supreme, particularly in the life sciences sector.

A Bold Move

Last year, Siemens made a $5.1 billion acquisition of Dotmatics, a company specializing in AI-driven drug development. Busch hinted that this is just the beginning, with more deals on the horizon.

Building a Strong Data Backbone

In an interview with Bloomberg Television, Busch emphasized the importance of strengthening the data backbone for life sciences. He believes that the future of drug development lies in leveraging data to create better drugs, faster.

Beyond Life Sciences

Siemens is also eyeing operations software, the technology that powers factories and keeps operations running smoothly. Busch sees substantial potential in this area as well.

What's Next?

While Siemens remains tight-lipped about their next moves, one thing is clear: they are not afraid to make big bets, and they are far from done.